ATLANTA, May 27 /PRNewswire-FirstCall/ -- CryoLife, Inc. , a biomaterials, medical device and tissue processing company, announced today that it is scheduled to participate in the FBR Capital Markets Annual Spring Investor Conference, Thursday, May 29, 2008 at the Grand Hyatt Hotel in New York City.
Steven G. Anderson, president and chief executive officer of CryoLife, Inc., will present at 12:50 p.m. Eastern Time.
CryoLife’s live presentation may be accessed through its Web site, www.cryolife.com, on the Investor Relations page. An archived copy of the presentation will be available for 90 days on the same Web site.
About CryoLife
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company recently received FDA clearance for the CryoValve(R) SG pulmonary human heart valve, processed using CryoLife’s proprietary SynerGraft(R) Technology. The Company’s BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. CryoLife distributes Hemostase MPH, a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom and Germany for cardiac, vascular and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O’Brien(R) stentless porcine heart valve, which is CE marked for distribution within the European Community.
For additional information about the Company, visit CryoLife’s Web Site: http://www.cryolife.com.
CONTACT: D. Ashley Lee, Executive Vice President, Chief Financial Officer
and Chief Operating Officer, CryoLife, Inc., +1-770-419-3355; or Katie
Brazel, Fleishman Hillard, +1-404-739-0150
Web site: http://www.cryolife.com//
